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Available online 31 October 2015A deﬁnitive cure for chronic myeloid leukemia (CML) requires identifying novel therapeutic targets to eradicate
leukemia stem cells (LSCs). However, the rarity of LSCs within the primitive hematopoietic cell compartment re-
mains a major limiting factor for their study in humans. Here we show that primitive hematopoietic cells with
typical LSC features, including adhesion defect, increased long-term survival and proliferation, and innate resis-
tance to tyrosine kinase inhibitor (TKI) imatinib, can be generated de novo from reprogrammed primary CML
cells. Using CML iPSC-derived primitive leukemia cells, we discovered olfactomedin 4 (OLFM4) as a novel factor
that contributes to survival and growth of somatic lin−CD34+ cells from bone marrow of patients with CML in
chronic phase, but not primitive hematopoietic cells from normal bone marrow. Overall, this study shows the
feasibility and advantages of using reprogramming technology to develop strategies for targeting primitive
leukemia cells.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
CML is a myeloproliferative disorder characterized by unregulated
growth of predominantly myeloid cells, and their subsequent
accumulation in the bonemarrow and peripheral blood. CML originates
in hematopoietic stem cells (HSCs) with t(9;22)(q34;q11.2) transloca-
tion, which causes the constitutive expression of the BCR-ABL kinase
driving the expansion of leukemic progeny (Holtz et al., 2002;
Holyoake et al., 2001; Ramaraj et al., 2004). Ex vivo cultures of CML-
derived cell lines and primary CML cells, ectopic expression of BCR-
ABL in CD34+ cells andmousemodels have provided important insights
into CML pathogenesis and led to the development of targeted therapy
for this neoplastic disease with BCR-ABL tyrosine kinase inhibitor (TKI),
imatinib (Druker et al., 2006; Druker et al., 2001). Despite these
achievements, eradication of CML remains challenging. Although the
majority of patients treated with imatinib achieve a complete cytoge-
netic response, discontinuation of imatinib treatment is commonly as-
sociated with relapse (Mahon et al., 2010). Multiple lines of evidenceenter, University of Wisconsin,
. This is an open access article undersuggest that the major cause of disease persistence is innate resistance
of leukemia stem cells (LSCs) to TKIs (Corbin et al., 2011; Graham et
al., 2002; Holyoake et al., 2001). Thus, studies of primitive leukemia
cells are essential for better understanding leukemia pathogenesis and
developing curative therapies for CML. Due to the limited number of
BCR-ABL+ cells within the most primitive hematopoietic cell compart-
ments (Holyoake et al., 1999; Holyoake et al., 2001; Vargaftig et al.,
2012), establishing technologies for de novo generation of LSC-like
cells would provide a signiﬁcant beneﬁt to the CML ﬁeld.
Reprogramming human somatic cells to pluripotency allows for the
generation of induced pluripotent stem cells (iPSCs) that behave simi-
larly to embryonic stem cells (ESCs), i.e., they are capable of self-
renewal, large-scale expansion, and differentiation toward derivatives
of all three germ layers, including blood (Choi et al., 2009b; Park et al.,
2008; Takahashi et al., 2007; Yu et al., 2009). Because iPSCs capture
the entire genome of diseased cells, they are already being used in
modeling human genetic diseases (Grskovic et al., 2011). Recently, we
and other groups successfully generated iPSCs from primary CML cells
and showed that CML-iPSCs capture the genetic alterations present in
leukemia cells, and possess the ability to produce differentiated leuke-
mia cells (Bedel et al., 2013; Hu et al., 2011; Kumano et al., 2012).
Here, we tested the hypothesis that reprogramming CML cells tothe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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used as a novel approach to produce an unlimited number of primitive
hematopoietic cells with LSC properties and identify novel primitive
leukemia cell survival factors and drug targets. We validated this hy-
pothesis by demonstrating the successful application of the iPSC-based
platform to discover OLFM4 as a novel primitive leukemia cell survival
factor in patients in the chronic phase of CML. This ﬁnding provides a
basis for development of novel approaches for treating CML by targeting
OLFM4 or OLFM4-mediated signaling pathways in primitive leukemia
cells.
2. Results
2.1. Generation of LSC-like cells from CML-iPSCs
Recently we generated transgene-free iPSCs from the bone marrow
mononuclear cells of a patient with a newly diagnosed CML in the
chronic phase (CML15 iPSCs and CML17 iPSCs) and showed that these
iPSCs capture the entire genomeof neoplastic cells, including theunique
4-way translocation between chromosomes 1, 9, 22, and 11 that was
present in the patient bone marrow (BM) (Hu et al., 2011). Sequencing
analysis revealed that the BCR-ABL translocation in these CML-iPSCs ex-
presses the p210 oncoprotein with a typical b3a2 rearrangement and
lack of mutations in the kinase domain (Supplementary Fig. S1a and
b). These ﬁndings were consistent with the observed sensitivity of pa-
rental bone marrow progenitors to imatinib (Supplementary Fig. S1c).
CML LSCs have been identiﬁed within the most primitive hemato-
poietic compartments as cells with long-term culture initiating cell
(LTC-IC) or in vivo repopulating activities. (Corbin et al., 2011; Li et al.,
2012; Petzer et al., 1996; Sloma et al., 2010; Udomsakdi et al., 1992b)
Similar to normal HSCs, CML LSCs express typical markers of primitive
hematopoietic cells including, CD34 and CD90, and are negative for he-
matopoietic lineage markers (lin−) and CD45RA (Udomsakdi et al.,
1992b). They also have high aldehyde dehydrogenase (ALDH) activity
and are able to efﬂux Rhodamine-123 (Udomsakdi et al., 1992a). Since
we previously found that cells with such features can be generated
from karyotypically normal iPSCs by coculture with OP9 (Choi et al.,
2009a; Choi et al., 2009b; Vodyanik et al., 2005), we used this system
to induce hematopoietic differentiation from CML iPSCs.
In OP9 coculture, CML iPSCs and control bonemarrow-derived iPSCs
(BM1K and BM9) formed CD34+CD43+ hematopoietic progenitors, in-
cluding CD235a−CD41a−CD45+ cells that are highly enriched in mye-
loid progenitors (Hu et al., 2011; Vodyanik et al., 2006) (Fig. 1a and
b). As shown in Fig. 1b, CD235a−CD41a−CD45+ cells obtained at day
9 of CML iPSC differentiation had the phenotypic features of CML LSCs
including the expression of the primitive hematopoietic cell markers
CD34, CD90 and CD117, and an absence of CD38 and CD45RA and line-
age markers (lin−). Similar to somatic CML LSCs, day 9 CML iPSC-
derived CD45+ cells had ALDH activity and were able to efﬂux
Rhodamine-123 (Fig. 1c-d). After expansion for 2 days, CD45+ cells
retained expression of CD34 and CD90 and CD117 stem cell markers
and remained lin− and CD45RA−. However, up to 25% of the population
acquired CD38 expression (Fig. 1b, day 11) and the levels of ALDHhigh
and Rholow cells within CD45+ population decreased (Fig. 1c and d).
CML iPSC-derived lin−CD34+CD90+CD117+CD45+38+/− (hereafter
referred to as induced CD34+; iCD34+) cells acquired expression ofmy-
eloid lineage-speciﬁc markers and lost CD34 expression (Fig. 1b, day
15), i.e. became lin+CD34− (hereafter referred to as induced CD34−
cells; iCD34−) following further culture with hematopoietic cytokines.
Thus, we concluded that cells with the LSC phenotype could be generat-
ed de novo from reprogrammed CML cells (Fig. 1e).
Although CML LSCs share many properties with HSCs, they have
three distinct characteristics: the increased proliferation and long-
term survival (Corbin et al., 2011; Holyoake et al., 1999); the ability to
grow in vitro without added cytokines (Jiang et al., 1999); and an adhe-
sion defect (Bhatia et al., 2001; Verfaillie et al., 1992). Therefore, nextweevaluated whether de novo generated CML iCD34+ cells possess similar
properties. By analyzing the growth of iCD34+ cells in serum-freemedi-
um with growth factors, we found an enhanced expansion of
iCD34+CD38− cells from CML iPSCs relative to similar cells fromnormal
BM iPSCs. Treatment with imatinib decreased expansion of CML
iCD34+CD38− cells to the level observed in normal BM iCD34+CD38−
cultures (Fig. 2a). CML iCD34+CD38− cells also generated signiﬁcantly
more and larger myeloid colonies as compared to normal BM
iCD34+CD38− cells (Fig. 2b). Although we did not see differences in
the number of colonies between CML and BM cells within CD38− com-
partment, CML iCD34+CD38− cells consistently generated larger colo-
nies. Using the LTC-IC assay, we found that CML iCD34+ cells
produced a much higher number of LTC-IC-derived CFCs than BM
iCD34+ cells, indicating an increase in long-term survival (Fig. 2c). In
serum-free cultures, CML iCD34+ cells were able to withstand growth
factor deprivation in both CD38+ and CD38− compartments, which
was reversed by treatment with imatinib (Fig. 2d). CML iCD34+ cells
also showed reduced adhesion to ﬁbronectin (Fig. 2ei), which was
partially restored by imatinib treatment (Fig. 2eii). Overall, these ﬁnd-
ings provide strong evidence that iCD34+ cells derived from CML
iPSCs behave similarly to their somatic LSC counterparts (Fig. 2f).
2.2. Induced LSC-like cells are resistant to imatinib
The dependence of CML cells on BCR-ABL signaling enables the sup-
pression of the disease by TKIs. However, resistances of CML LSCs to i-
matinib preclude a complete cure for CML (Corbin et al., 2011;
Graham et al., 2002; Holyoake et al., 2001). Analysis of BCR-ABL expres-
sion by qPCR and Western blot demonstrated that BCR-ABL mRNA and
protein, including phosphorylated protein (p-BCR-ABL) were present in
undifferentiated CML iPSCs and their iCD34+ and iCD34− progeny
(Fig. 3a and b). Interestingly, expression of BCR-ABL mRNAwas greater
in undifferentiated CML iPSCswhen compared to parental bonemarrow
CD34+ cells. However, in iCD34+ cells, the level of BCR-ABL expression
downregulated to the level observed in parental CD34+ cells. Evaluation
of the phosphorylation status of the BCR-ABL-speciﬁc substrate CRK-
like protein (CRKL) revealed the presence of a phosphorylated form of
CRKL (p-CRKL) in CML, but not in the control BM iCD34+ and iCD34−
cells (Fig. 3c), thus providing evidence that BCR-ABL is active in CML
iPSC-derived hematopoietic progeny.
Studies in CML patients have shown that imatinib inhibits BCR-ABL
kinase and cell proliferation in primitive hematopoietic compartments
without affecting survival of LSCs (Copland et al., 2006; Corbin et al.,
2011; Graham et al., 2002; Holtz et al., 2002; Schemionek et al., 2010).
To ﬁnd out whether de novo generated CML iCD34+ cells respond to i-
matinib in a similar fashion, we evaluated the effect of imatinib on
these cells in vitro. After treatment with imatinib for 4 h, p-CRKL dra-
matically decreased in both primitive iCD34+ and in more mature
iCD34− blood cells (Fig. 3c and d). This indicates that imatinib efﬁciently
inhibits the majority of BCR-ABL kinase activity in de novo generated
CML cells, independent of the stage of maturation. The inhibition of
BCR-ABL kinase in iCD34− cells by imatinib treatment was associated
with increased apoptosis as determined by using Annexin V staining
and caspase 3/7 ﬂuorogenic substrate (Fig. 3e and ﬁi). In contrast, ima-
tinib failed to induce apoptosis in CML iCD34+ cells (Fig. 3ﬁ), despite the
abrogation of p-CRKL signaling in these cells (Fig. 3c and d). The in-
creased resistance to imatinib within the more primitive hematopoietic
compartment was also evident from a signiﬁcant increase of inhibitory
concentration 50% (IC50) for CML iCD34+ cells as compared to CML
iCD34− cells (Fig. 3gi). Both, iCD34+ and iCD34− cells, generated from
normal BM iPSCs, were not affected by imatinib treatment (Fig. 3ﬁ, ﬁi
and gii).
To conﬁrm the maturation stage-dependent sensitivity to imatinib,
we analyzed the distribution of apoptotic cells within different com-
partments and generations following expansion of CFSE-labeled CML
iCD34+ cells. Imatinib treatment of CML iCD34+ cell cultures was
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(generations 2–4) in bulk cultures (Supplementary Fig. S2a and b) and
retention of CD34+ expression by rapidly dividing cells (generations
5–7; Supplementary Fig. S2c) as compared to non-treated cells. Annexin
V staining of CFSE-labeled cell cultures revealed that themost primitive
iCD34bright cells were resistant to imatinib-induced apoptosis, while a
substantial increase in apoptosis was observed in iCD34− cells and in
more mature and proliferative iCD34dim cells the majority of which
were CD38+ (Supplementary Fig. S2d–f). These ﬁndings imply that dif-
ferentiated CML iCD34− cells became sensitive to imatinib and could
not survive in culture, while the most primitive CML iCD34+CD38−
cells did not undergo apoptosis upon imatinib treatment and were
selected to dominate in the culture.
Taken together, these results indicate that CML iCD34+ cells repro-
duce many aspects of drug resistance observed in somatic primitive he-
matopoietic cells from CML patients in the chronic phase (Fig. 3h).
2.3. Identiﬁcation of olfactomedin 4 as a novel survival factor in LSC-like
cells
To ﬁnd out whether CML iPSC-derived primitive hematopoietic cells
can be used to discover novel LSC survival factors and drug targets, we
compared the molecular proﬁle of CML and normal BM iCD34+ cells
that were either treated or not treated with imatinib for 16 h in expan-
sion cultures with cytokines. Similar to the ﬁndings with somatic CML
CD34+ cells (Leng et al. 2013; Li and Dewey 2011), untreated CML
iCD34+ cells showed signiﬁcant differences compared to normal BM
iCD34+ cells in the expression of genes regulating chemotaxis, adhe-
sion, cytokine production, proliferation, programmed cell death, regula-
tion of phosphorylation, and fatty acid metabolism (Supplementary
Fig. S3a). These differences included the upregulation of genes associat-
ed with cancer development, such as BCL2, CDK6, PRKCQ, MYCN,
CDKNA2A, GFI1B, TP53RK, and RASGRP3, and the downregulation of ad-
hesion molecules ICAM1, ICAM3, ITGB2 and ITGB7 (Supplementary
Fig. S3b and Supplementary Table S1). We next evaluated the effect of
imatinib on the transcriptome of iCD34+ cells by performing principal
component analysis (PCA) to deﬁne the change in transcriptional dis-
tance following drug treatment. As shown in Fig. 4a, after treatment
with 5 μM imatinib, CML iCD34+ cells moved away from non-treated
CML iCD34+ cells toward non-treated control BM iCD34+ cells in the di-
mension deﬁned byprincipal component PC1 and PC2, i.e. becamemore
similar to control BM iCD34+ cells, thereby suggesting the important
role of BCR-ABL signaling in establishing the unique transcriptional sig-
nature of neoplastic cells in CML.
To ﬁnd candidate genes associated with imatinib resistance, we ini-
tially selected genes that were signiﬁcantly upregulated or downregu-
lated by imatinib in CML iCD34+ cells. From the list of upregulated
genes, we chose 137 that were induced ≥2 fold by imatinib treatment
(Fig. 4b). Then, we selected genes that were upregulated in CML
iCD34+ cells, but suppressed in BM iCD34+ cells, i.e. excluded genes
that were upregulated or not affected by imatinib in BM iCD34+ cells
(Fig. 4b and c and Supplementary Table S2). A similar algorithmwas ap-
plied for down-regulated genes. From the list of signiﬁcantly
dowregulated genes, we chose those that were suppressed ≥2 fold by
imatinib in CML iCD34+ (16 genes). We then selected genes that were
suppressed in CML iCD34+ cells, but upregulated in BM iCD34+ cells
(Fig. 4b and c and Supplementary Table S2). Overall, based on this selec-
tion algorithm we identiﬁed 127 upregulated and 11 downregulated
genes following imatinib treatment. Upregulation of selected genesFig. 1. Generation of lin−CD34+CD43+CD45+ primitive hematopoietic cells from CML-iPSCs. (
ignation are shown under and on the top of cells, respectively. Preﬁx i indicates iPSC-derived. F
iPSCs after differentiation on OP9 (day 9) and following their expansion/differentiation with cy
speciﬁc antibody (shaded) histograms. Representative results from three to four independent e
CML iCD34+ cells. Representative dot plots showRho efﬂuxand ALDHactivity in CD34+CD38+
assay (dii). The values aremean± SEM of % of Rholow cells (% of Rholowverapamil−− Rholowverapam
tively. DEAB= diethylaminobenzaldehyde, ALDH= aldehyde dehydrogenase. (e) Summary o(BCL2A1, ALOX15 and SMAD7) by imatinib in CML iCD34+ cells was con-
ﬁrmed by qPCR analysis (Supplementary Figure S3c). Interestingly, the
top-ranking up-regulated gene identiﬁed by our algorithm was OLFM4
(olfactomedin 4), which has been reported to have anti-apoptotic activ-
ity in malignancy (Liu et al., 2012; Oh et al., 2011; Zhang et al., 2004).
According to AceView analysis (Thierry-Mieg and Thierry-Mieg,
2006), transcription of human OLFM4 produces 5 different mRNAs
(OLFM4a–OLFM4e) encoding four alternatively spliced variants and
one unspliced variant. These mRNAs encode four complete proteins, in-
cluding OLFM4a and OLFM4d secreted isoforms and OLFM4b and
OLFM4c cytoplasmic isoforms. OLFM4e isoform is reconstructed from
partial mRNA and is not fully characterized (http://www.ncbi.nlm.
nih.gov/IEB/Research/Acembly/av.cgi?db=human&c=Gene&l=
OLFM4). Using isoform speciﬁc primers, we demonstrated the pres-
ence of four out of ﬁve OLFM4 mRNA isoforms (OLFM4a–OLFM4d)
in CML iCD34+ cells and the entire set of ﬁve mRNA isoforms
(OLFM4a–OLFM4e) in CML iCD34− cells (Supplementary Fig. S4a).
Consistent with RNAseq data, qPCR analysis revealed the augmenta-
tion of OLFM4 expression by imatinib in CML iCD34+ cells, including
all four OLFM4a–OLFM4d mRNA isoforms (Fig. 4d).
To evaluate the potential role of OLFM4 in survival of CML iCD34+
cells, we tested the effect of OLFM4 knocking-down on iCD34+ cell ap-
optosis using OLFM4-targeted small interference RNA (siOLFM4) com-
posed of four OLFM4-speciﬁc siRNAs. Transfection of CML iPSC-derived
hematopoietic cells with this set of siRNAs enables 60%–85% reduction
in expression of all ﬁve OLFM4 mRNA isoforms (Supplementary
Fig. S4b). As shown in Fig. 4e, imatinib or siOLFM4 had no effect on
CML iCD34+ cell apoptosis. However, siOLFM4 treatment in the pres-
ence of imatinib induced signiﬁcant increase of apoptosis in CML, but
not normal bone marrow iCD34+ cells. In addition, OLFM4 knockdown
selectively inhibited expansion of CML iCD34+ cells in vitro (Fig. 4f).
These ﬁndings imply that OLFM4 is involved in regulation of imatinib
resistance and survival of de novo generated primitive CML cells
(Fig. 4g).
2.4. OLFM4 is essential for somatic primitive leukemia cell survival in vitro
and in vivo engraftment
To ﬁnd out whether the ﬁndings obtained using iCD34+ cells can be
translated to somatic cells, we isolated lin−CD34+ cells (hereafter re-
ferred to as sCD34+) form parental bone marrow (patient 1; P1) and
bone marrow from several other CML patients in the chronic phase.
Using RT-PCR, we detected OLFM4 mRNAs in sCD34+ cells isolated
from all CML patients. However, in contrast to iCD34+ cells generated
de novo fromCML iPSCs, sCD34+ cells fromCMLpatients expressed a re-
stricted range of OLFM4 isoforms (Fig. 5a and b). Cytoplasmic OLFM4b
isoform was found in sCD34+ cells from all CML patients, while none
of the patients showed expression of isoform OLFM4e. The expression
of cytoplasmic OLFM4c isoform, and secreted OLFM4a and OLFM4d iso-
forms varied between patients, but none of the patients expressed the
entire range of isoforms. In contrast, sCD34− cells expressed all range
of isoforms, although isoform e was not detected in some patients
(Fig. 5a and b). None of the OLFM4 isoforms were detectable in normal
bone marrow sCD34+ cells by PCR (Fig. 5a). To examine whether
OLFM4 is expressed in primitive CML cells in situ, we performed immu-
noﬂuorescent staining of BM biopsies from normal individuals and pa-
tients in the chronic phase of CML. As shown in Fig.5c, OLFM4 was
detected in CD34+ cells from CML patients, but not in normal donors.
In contrast, CD34− cells showed OLFM4 protein expression in botha) Schematic diagram of hematopoietic differentiation from iPSCs. Phenotype and its des-
SGm36= Flt3L, SCF, GM-CSF, IL3, IL6. (b) Phenotypes of CD45+ cells obtained from CML-
tokines in stroma-free cultures (as indicated in A). Plots show isotype control (open) and
xperiments are shown. (c) and (d) Rhodamine (Rho) efﬂux and ALDH activity in isolated
and CD34+CD38− populations (c). Graph shows quantiﬁcation of Rho efﬂux (di) andALDH
il+) andALDH+ cells (% of ALDH+DEAB−− ALDH+DEAB+) from three experiments respec-
f ﬁndings.
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most primitive CML cells, we evaluated OLFM4 secretion by sCD34+
(lin−CD34+) cells isolated from P1 and P6 following the short-term
in vitro cultures. Using ELISA, we detected OLFM4 protein in sCD34+
cultures from CML patients, while the OLFM4 levels in control BM
cultures were not exceeded background level (Fig. 5d). Since previous
studies have demonstrated the induction of OLFM4 expression by G-
CSF in myeloid progenitors (Chin et al., 2008; Zhang et al., 2002), we
tested whether G-CSF enhances OLFM4 production in sCD34+ cells
from CML patients. We found that G-CSF stimulation indeed enhances
OLFM4 production by sCD34+ cells and that this effect is potentiated
by imatinib (Fig. 5d). To conﬁrm the speciﬁcity of G-CSF effect, we cul-
tured sCD34+ cells from patient P6 with G-SCF and G-SCF blocking
monoclonal antibody. The level of OLFM4 production in presence of an-
tibody was reduced from 205 pg/ml to 47.5 pg/ml.
To assess whether OLFM4 provides a survival advantage for CML
sCD34+ cells, we performedCFC assay after a 24 h treatmentwith imatin-
ib, siOLFM4, or both. Consistent with prior observations in iCD34+ cells,
CML cells in clonogenic cultures displayed a signiﬁcant upregulation of
OLFM4 expression when pretreated with imatinib (Fig. 6a and Supple-
mentary Fig. S5). The OLFM4a mRNA isoform was the most abundant
in these cultures (Fig. 6a), while other isoforms were expressed at
much lower levels (Supplementary Fig. S5). Knockdown of OLFM4 in
CML sCD34+ cells using siRNA potentiated the inhibitory effect of ima-
tinib on CFCs, which was reversed by pretreatment of cells with OLFM4
protein (Fig. 6b). In contrast, no signiﬁcant effect was observed follow-
ing similar treatments of sCD34+ cells from BM of three normal donors
(Fig. 6b).
To determinewhether OLFM4provides a survival advantage for cells
more primitive than CFCs and whether it can affect the response of
these cells to imatinib, we performed an LTC-IC assay using CML
sCD34+ cells treated with siOLFM4, imatinib or both together. Consis-
tent with previous studies (Bellodi et al., 2009; Corbin et al., 2011), ima-
tinib had little effect on somatic LTC-ICs. In contrast, treatment of cells
with siOLFM4 signiﬁcantly reduced OLFM4 production in sCD34+ cul-
tures (Fig. 6c) and the number of colonies in LTC-IC cultures (Fig. 6d
and Supplementary Table S3). Addition of imatinib to siOLFM4-treated
cultures had no signiﬁcant impact on LTC-IC numbers (Fig. 6d). Both i-
matinib and siOLFM4 treatment did not affect substantially the propor-
tion of BCR-ABL positive colonies from LTC-IC cultures (Supplementary
Table S4). The observed effect of OLFM4 knockdown on the LTC-ICs was
different from the one we observed with less primitive leukemia cells,
CFCs. While OLFM4 downregulation alone had minimal effect on CFCs,
it signiﬁcantly augmented the inhibitory effect of imatinib on these pro-
genitors. In contrast, OLFM4 knockdown alone was able to abrogate
LTC-ICs and no synergistic action was observed between OLFM4 knock-
down and imatinib treatment, thereby suggesting that OLFM4-
mediated survival of the most primitive CML cells may not depend on
BCR-ABL tyrosine kinase-mediated signaling. Although our studies indi-
cate that knockdown of OLFM4 in sCD34+ cells affects primitive CML
cell survival in vitro, it remains unclear whether this effect is mediated
through cell-intrinsic pathways or through paracrine signaling. Follow-
ing culture, lin−CD34+ cells undergo differentiation into lin+CD34−
cells, that highly express OLFM4. Since siRNAs are transferred to cells
following cellular division and the duration of RNA silencing in rapidlyFig. 2. Stem/progenitor cell properties of CML and control BM iPSC-derived iCD34+ cells. (a) Exp
in presence of DMSO (control) or 5 μM imatinib. Results are mean ± SEM from six independen
CML17 iCD34+). * indicates signiﬁcant differences between cell counts in BM and CML iCD34+
treated and untreated CML iCD34+ cells (p b 0.05). (b) Colony formation from BM and CML iC
panels show typical GM colony from BM and CML iCD34+ cells. Both, CML iCD34+CD38− and
iCD34+ cells. (c) LTC-IC assay of CML and BM iCD34+ cells. Numbers next to the plot show the t
two biological replicates performed in triplicates. Representative colony and Wright stained c
shown below the chart. Scale bar = 100 μm. (d) Expansion of CML and BM iCD34+ cells in se
5 μM imatinib. Results are mean± SEM from six independent experiments (three from each BM
icant differences between cell counts in BM and CML iCD34+ cultureswithout imatinib (p b 0.05
cells (p b 0.05). (e) Adhesion of BMand CML iCD34+ cells to ﬁbronectin or control bovine serum
to ﬁbronectin (eii). * p ≤ 0.02. Results are mean ± SEM from three independent experiments.dividing cells approaches 1 week (McIntosh et al. 2014), siOLFM4
knockdown most likely reduces OLFM4 production in primitive
sCD34+ cells as well as in CD34− cells differentiated from sCD34+
cells. Thus, OLFM4 secreted by differentiated cells (neoplastic and
non-neoplastic) may provide survival cues to primitive CML cells.
The ability to engraft in immunocompromised mice is used as im-
portant criterion to identify LSC function. However, hematopoietic
cells derived from human pluripotent stem cells have markedly im-
paired engraftment capacity (Slukvin, 2013; Vo and Daley, 2015). Al-
though previous mouse studies have found that forced retroviral
expression of BCR-ABL in hematopoietic progenitors generated from
pluripotent embryonic stem cells endowed themwith engraftment po-
tential (Perlingeiro et al., 2001), we failed to detect meaningful engraft-
ment following transplantation of CML iPSC-derived iCD34+ cells (not
shown). This could be related to a more “physiological” level of BCR-
ABL expression in de novo generated human primitive leukemia cells
that could be insufﬁcient to enable their engraftment. Therefore, to as-
sess the role of OLFM4 in vivo, we performed transplantation of somatic
lin−CD34+ cells from CML patients in chronic phase using NOD,B6.SCID
IL2Rγ−/− KitW41/W41 (NBSGWmice possessing a defective Kit allele;
c-kit, W41) (McIntosh et al., 2014). Mice models with a defective Kit al-
lele support engraftment of human cells without irradiation, and are su-
perior to irradiated mice for transplantation of human leukemia cells
(Cosgun et al., 2014; McIntosh et al., 2014). Using NBSGW mice we
were able to detect human CD45+ cells in bone marrow following
transplantation as low as 10,000 lin−CD34+ cells from patients in
chronic phase of CML. As shown in Fig. 7a and b, most of the NBSGW
mice transplanted with scrambled siRNA-transfected CML sCD34+
cells demonstrated the presence of human CD45+ cells in bonemarrow.
In contrast, only two out eight mice transplanted with siOLFM4-
transfected sCD34+ cells showed detectable human CD45+ cells at
much lower levels compared to corresponding mice in scrambled
siRNA group. RT-PCR analysis conﬁrmed that engrafted human CD45+
cells expressed BCR-ABL (Fig. 7c). Thus, these studies provide the evi-
dence that OLFM4 is important for the engraftment of primitive leuke-
mia cells in vivo, although it has yet to be determined whether OLFM4
knockdown affects bone marrow homing or in vivo survival of CML
lin−CD34+ cells.
3. Discussion
Multiple studies have already demonstrated the validity of the iPSC
model for studying pathogenesis of monogenic human diseases and
drug screening (reviewed in (Rais et al., 2013)). Although the potential
use of iPSC technology in studying neoplasia has been suggested
(Ramos-Mejia et al., 2012; Slukvin, 2009; Ye et al., 2009), only a few
groups have reported the generation of iPSCs from malignant cells. The
ﬁrst successful reprogramming of cancer cells was achieved by
Hochedlinger, who generated mouse pluripotent stem cells by
transplanting nuclei from melanoma into oocytes (Hochedlinger et al.,
2004). After the discovery of pluripotency factors capable of
reprogramming blood cells, iPSC lines have been generated from a pa-
tient with a myeloproliferative disorder bearing the JAK2-V617F muta-
tion (Ye et al., 2009), CML cell lines (Carette et al., 2010), primary bone
marrow cells of chronic phase CML patients (Bedel et al., 2013; Hu etansion of CML and BM iCD34+ cells in serum-freemedium(SFM)with growth factors (GF)
t experiments (three from each BM1K and BM9 iCD34+, and three from each CML15 and
cultures without imatinib (p b 0.05).Ψ indicates signiﬁcant differences between imatinib
D34+ cells. Graph shows mean ± SEM from 3 independent experiments. * p b 0.01. Right
iCD34+CD38+ cells grew much larger colonies in CFC medium as compare to control BM
otal number of CFCs detected in LTC-IC cultures of iCD34+ cells. Results aremean± SEMof
ytospin from the colony formed by CML iCD34+ cells after 5 weeks of LTC-IC culture are
rum-free medium (SFM) without growth factors (GF) in presence of DMSO (control) or
1K and BM9 iCD34+, and three from each CML15 and CML17 iCD34+). * indicates signif-
).Ψ indicates signiﬁcant differences between imatinib treated and untreated CML iCD34+
albumin (BSA)-adsorbed plates (ei) and the effect of imatinib on adhesion of iCD34+ cells
(f) Summary of ﬁndings.
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(Gandre-Babbe et al., 2013), and mouse MLL-AF9 leukemia cells (Liu et
al., 2013). These studies demonstrated that iPSCs generated from neo-
plastic cells carry a disease-speciﬁc genetic mutation and can be used to
generate blood cells affected by that particular mutation. Here, we ad-
vanced the iPSC model to study primitive leukemia cells and proved the
utility of this model for discovering drug targets by identifying the
novel CML LSC survival factor OLFM4.
The iPSC technology offers several major beneﬁts for studying CML.
Current protocols for obtaining primitive CML cells are based on selec-
tion of lin−CD34+ cells from patient bone marrow samples. However,
this approach does not reliably isolate LSCs because normal primitive
hematopoietic cells usually outnumber BCR-ABL+ cells within the lin−
CD34+ compartment by several folds (Petzer et al., 1996). The capacity
of iPSCs to capture CML genetic aberrations, self-renew indeﬁnitely and
differentiate into blood cells allows for the production of pure popula-
tions of patient-speciﬁc BCR-ABL+ LSC-like cells in unlimited numbers
for functional studies and drug screening. As shown in present studies,
the use of pure population of induced lin−CD34+CD90+CD117+-
CD45
+
CD38+/− BCR-ABL+ cells enabled identiﬁcation of genes affected
by imatinib treatment and eventually led to discovery of novel survival
factor for primitive leukemia cells OLFM4. iPSCs can be genetically
modiﬁed to generate CML iPSC lines in which speciﬁc gene expres-
sion can be conditionally manipulated, thereby facilitating the iden-
tiﬁcation of genes regulating human LSCs' survival and expansion.
iPSCs obtained from the patients before and after acquisition of
drug resistance or progression to blast crisis would be a valuable
tool for studying the molecular mechanisms of CML progression
and drug resistance. Understanding the impact that clonal evolution
and diversity has on CML progression requires the selection and ex-
pansion of individual leukemia clones; and this represents the major
technical challenge. Because iPSCs are of a single cell origin, multiple
iPSC lines can be generated from the same patient to capture the di-
versity of genetic alterations within leukemia cell populations and
address the role of non-BCR-ABL-associated mutations in disease
development.
Another important ﬁnding of this study is the discovery of OLFM4
as a novel survival factor for primitive CML cells. The human OLFM4
(also called GW112 and hGC-1) gene encodes a glycoprotein with a
multimer structure (Liu et al., 2006). Transcription for this gene pro-
duces four spliced variants and one unspliced OLFM4a–OLFM4e
mRNA isoforms encoding secreted and cytoplasmic proteins
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=
human&c=Gene&l=OLFM4). OLFM4 plays an important role in a
variety of cellular functions including cell adhesion, cell cycle and
apoptosis (Tomarev and Nakaya, 2009). In the human intestine,
OLFM4 was identiﬁed as a robust marker of LGR5+ stem cells and a
subset of cancer cells (van der Flier et al., 2009). OLFM4 is involved
in cell growth and apoptosis in human malignancies (Liu et al.,
2010; Oh et al., 2011; Park et al., 2012; Zhang et al., 2004) and is con-
sidered to be an inducible resistance factor to apoptotic stimuli
(Koshida et al., 2007). OLFM4 interacts with GRIM-19 (Zhang et al.,
2004), which is a component of the respiratory complex I of mito-
chondria with an anti-apoptotic role in prostate cancer cells
(Huang et al., 2004). However, the effects of OLFM4 on apoptosis ap-
pear to be a cell-type dependent. In contrast to prostate cancer cells,Fig. 3. Effects of imatinib on CML iPSC-derived iCD34+ cells. (a) Western blot shows expressio
hematopoietic derivatives. GAPDH and K562 were used as a loading control and a positive c
their derivatives and paternal sCD34+ bone marrow cells. The expression levels were calculate
plicate. (c)Western blot shows phospho-CRKL (p-CRKL) expression in iCD34+ and iCD34− cell
trol. (d) Quantitative analysis of p-CRKL expression by densitometry. Results are calculated as p
mean ± SEM from three independent experiments. (e) Dot plot shows staining of CML iCD34
DMSO. (f) Apoptosis in BM and CML iCD34+ (ﬁ) and iCD34− (ﬁi) cells treated and non-treat
are the mean ± SEM from three independent experiments. K562 was used as an IM-sensitive
marrow (gii) iCD34+ and iCD34− cells is shown as relative response (% of cell death relative to c
IC50 shift (p b 0.05). Results are the mean ± SEM from three independent experiments performoverexpression of OLFM4 in HL-60 leukemia cells induces their dif-
ferentiation and apoptosis (Liu et al., 2010). Although OLFM4 was
initially identiﬁed in myeloblasts and later in neutrophils
(Clemmensen et al., 2012; Zhang et al., 2002), OLFM4's biological
function in normal and neoplastic hematopoiesis remains largely un-
known. It has been shown that OLFM4 expression is upregulated in a
subset of patients with acute myeloid leukemia and primary myelo-
ﬁbrosis (Hasselbalch et al., 2014; Liu et al., 2010). Here, we demon-
strated the expression of OLFM4 protein in lin−CD34+ and CD34−
bone marrow cells from CML patients in chronic phase and revealed
the distinct pattern of OLFM4 isoform expression in these cells at the
mRNA level. CML lin−CD34+ cells expressed predominantly cyto-
plasmic OLFM4 mRNAs. In contrast, CML CD34− differentiated cells
displayed the broad spectrum of cytoplasmic and secreted
OLFM4a–OLFM4d isoforms. Using OLFM4 knockdown studies, we
discovered the critical role OLFM4 in the survival and drug resistance
of primitive CML cells and demonstrated differences in OLFM4-
mediated regulation of cell survival in CFCs and more primitive
LTC-ICs (Fig. 7d). While OLFM4 had a minimal role in CML CFC main-
tenance in normal conditions, it was required for protection of CML
CFCs from imatinib-mediated inhibition. In contrast, maintenance
of CML LTC-ICs was dependent on OLFM4 and independent of BCR-
ABL kinase activity. Consistent with in vitro LTC-IC studies, OLFM4
knockdown also abrogated the engraftment of BCR-ABL+ cells in
NBSGWmice, thereby providing another critical evidence for the es-
sential role of OLFM4 in homeostasis of CML cells in vivo. The mech-
anisms responsible for the distinct role of OLFM4 in the survival of
leukemia cells at different stages of maturation remain to be investi-
gated. It is possible that cell-context speciﬁc effects may be related to
differences in the expression and/or regulation of the OLFM4 iso-
forms in a stage-speciﬁc fashion. It is also important to investigate
whether OLFM4 mediates cell survival in a self-autonomous or
non-autonomous manner. Given that lin−CD34+ cells acquire a
CD34− differentiated phenotype which is associated with a high
level of OLFM4 expression in culture, it is possible that secretion of
OLFM4 by differentiated cells generates a milieu supportive for the
growth of undifferentiated CML cells in vitro. Similarly, we observed
that differentiated CD34− cells next to CD34+ cells in bone marrow
biopsy samples of CML patients express high levels of OLFM4. In ad-
dition, OLFM4 is produced by normal non-leukemic CD34− cells.
Thereby, OLFM4 secreted by differentiated leukemic or non-
leukemic cells may confer a selective growth advantage to the
more primitive CML cells and LSCs in vivo.
Overall, our studies indicate that OLFM4-mediated signaling sup-
ports the survival of primitive leukemia cells. Thus, analysis of OLFM4
and its isoforms in peripheral blood could be exploited as predictive
markers for treatment regimens, while targeting OLFM4 or OLFM4-
mediated signaling could be explored as anoption to eradicate primitive
CML cells. Potentially, OLFM4 could be targeted using anti-OLFM4 anti-
bodies. An antibody approach has already been described to modulate
the activity of another protein within the OLFM family, OLFM3. As
shownbyMiljkovic-Licina (Miljkovic-Licina et al., 2012), administration
of anti-OLFM3 antibodies efﬁciently blocked proangiogenic signaling
mediated by this protein in vivo. Finally, our studies provide a strong
background and novel model for the further exploration of the mecha-
nisms of OLFM4 action in primitive CML cells.n of BCR-ABL, c-ABL and p-BCR-ABL protein in normal BM iPSCs and CML iPSCs and their
ontrol respectively. (b) qPCR quantiﬁcation of BCR-ABL mRNA expression in CML iPSCs,
d relatively to K562 as calibrator. Results are mean ± SEM from three experiments in du-
s following 4 h treatment with 5 μΜ imatinib or DMSO. GAPDHwas used as a loading con-
-CRKL/GAPDH ratio. Graph shows % of inhibition relative to DMSO control. Results are the
− cells with Annexin V and caspase 3/7 detection agent after treatment with imatinib or
ed with 5 μM imatinib for 24 h. Apoptosis was evaluated by Annexin V staining. Results
control. * p b 0.05. (g) 50% Inhibition concentration (IC50) assay from CML (gi) and bone
ell death in the upper plateau) versus log concentration of imatinib. * indicates a signiﬁcant
ed in triplicate. (h) Summary of ﬁndings.
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4.1. iPSCs maintenance and hematopoietic differentiation
In this study, we used previously described transgene-free BM9,
CML15 and CML17 iPSCs produced by reprogramming of normal bone
marrow mononuclear cells and bone marrow mononuclear cells from
patient with newly diagnosed CML in the chronic phase (Hu et al.,
2011). BM1K iPSC was generated from the normal control using the
same approach (Hu et al., 2011). Undifferentiated iPSCs were main-
tained in cocultures with mouse embryonic ﬁbroblasts (MEFs).
Hematopoietic differentiation was induced by transferring the iPSCs to
overgrown OP9 feeders as we have previously described in detail
(Choi et al., 2009a; Vodyanik et al., 2005). VEGF (100 ng ml−1) was
added to some cultures at initiation of differentiation to enhance
blood production. CD43+ cellswere collected on day 9 of differentiation
using MACS and cultured in α-MEM supplemented with 10% FBS,
50 μg ml−1 ascorbic acid, 100 μMmonothioglycerol (complete serum
supplementedmedium (CSSM)) and 200 ngml−1 GM-CSF to selective-
ly expandmyeloid progenitors (Choi et al., 2009a). After two days of ex-
pansion with GM-CSF CD43+ cells enriched in myeloid progenitors
were cultured for an additional four days in the same media supple-
mented with 10 ng ml−1 IL-3, 100 ng ml−1 IL-6, 100 ng ml−1 Flt3L,
100 ng ml−1 SCF, and 200 ng ml−1 GM-CSF (all from Peprotech).
4.2. Isolation of lin−CD34+ cells from iPSC cultures
CD43+ hematopoietic cells were collected from differentiated iPSC
cultures using MACS and labeled with CD235a/CD41a FITC, CD45 APC
and CD38 PE (BD Pharmingen). Lin-CD45+CD38+ and lin-
CD45+CD38-subpopulations were obtained by ﬂuorescence-activated
cell sorting using FACSAria (BD) (Vodyanik et al., 2006).
4.3. Collection of bone marrow specimens from CML patients in the chronic
phase, and controls, and puriﬁcation of lin-CD34+ cells
Bone marrow mononuclear cells from CML patients in the chronic
phase were purchased commercially (AllCells or Applied StemCells),
or obtained from the patients at the University of Wisconsin Hospital
and Clinics (Madison,WI)with approval from theUniversity ofWiscon-
sin Institutional Review Board. Donors had previously signed an Institu-
tional Review Board-approved consent. Patients P1, P2, P5–P7 were
newly diagnosed with CML. All studied (P1–P7) patients were sensitive
to imatinib. Bonemarrow cells fromhealthy donorswere obtained from
Cincinnati Children's Hospital Medical Center (CCHMC). Mononuclear
cells were labeled with the lineage-speciﬁc markers CD2, CD3, CD14,
CD15, CD16, CD19, CD20, CD24, CD41a, CD56, CD66b, and Glycophorin
A (FITC-conjugated antibodies), CD34 APC (BD Pharmingen) and DAPI
to exclude dead cells. Live lin−CD34+ cellswere isolated using FACSAria
(BD). In some experiments, mononuclear cells were thawed and cul-
tured overnight followed by labeling and isolation of lin−CD34+ cells
as described above.Fig. 4. Gene expression analysis reveals set of imatinib-induced genes in CML iPSC-derived iCD
treated (IM+) and non-treated (IM-) with imatinib. After treatment with imatinib the position
candidate genes associated with imatinib resistance. Upper left Venn diagram shows genes sign
agram shows genes that were signiﬁcantly suppressed by imatinib (≥2 fold reduction). Genes w
ing expression of genes selectively induced or suppressed by imatininb in CML iCD34+. The top
CML/imatinib-treated BM iCD34+ cells. (d) qPCR analysis of the effect of imatinib treatment on
SEM of three experiments in duplicate. The expression levels were calculated relative to untrea
iCD34+ cells. Results are mean ± SEM of three independent experiments. The statistical differ
imatinib plus siOLFM4; * p b 0.05 (f) Effect of OLFM4 knockdown on BM or CML iCD34+ cell pro
cell numbers in cultures treated with siOLFM4 relative to cell numbers in corresponding cultu
ments. * indicates signiﬁcant (p b 0.05) decrease in the expansion cell ratios (siOLFM/scram
(g) Summary of ﬁndings.4.4. Hematopoietic colony-forming assay
Hematopoietic clonogenic assays were performed using serum-
containing StemMACS semisolid clonogenic medium (Miltenyi Biotec,
CA). Cells were incubated with either DMSO or 5 μM imatinib in
serum-free medium (SFM) composed of IMDM, 10% BIT (Stem Cell
Technologies), 2-mercaptoethanol, and EXCYTE (Millipore) and supple-
mented with a low concentration of growth factors (1 ng ml−1 of each
SCF, IL3, IL6, Flt3L and GM-CSF). After 24 h of cultures, cell collected and
plated in clonogenic medium without imatinib.
4.5. Rhodamine 123 exclusion aldehyde dehydrogenase activity assays
Rho exclusion assay was performed as previously described
(Vodyanik et al., 2005). Aldehyde dehydrogenase (ALDH) staining was
performedwith theAldeﬂuor kit (StemCell Technologies) permanufac-
turer instructions.
4.6. Apoptosis assay
CML iCD34+ cells were cultured in CSSM containing 10 ngml−1 IL3,
100 ng ml−1 IL6, 200 ng ml−1 GM-CSF, 100 ng ml−1 SCF, and
100ngml−1 Flt3Lwith orwithout 5 μMimatinib for 24h before analysis
of apoptosis. When indicated, cells were transfected with either OLFM4
or scrambled (control) siRNA. Cells were stained with Annexin-V–PE
and 7-AAD using the Annexin V: PE Apoptosis Detection Kit (BD Biosci-
ence) according to the manufacturer's protocol and analyzed by ﬂow
cytometry. In some experiments green Caspase 3/7 detection reagent
(Life Technologies) was used in combination with Annexin-V-PE stain-
ing to detect apoptotic cells.
4.7. Western blotting
Cells were cultured in serum-free mediumwithout growth factor in
the presence or the absence of 5 μM imatinib for 4 h prior to harvesting.
Lysates were prepared in RIPA buffer containing 1% Nonidet P-40 and
1% sodium deoxycholate supplemented with 1 mM
phenylmethylsulfonyl ﬂuoride, protease inhibitors cocktail and 1 mM
sodium vanadate. Proteins were separated by SDS-PAGE, transferred
to nitrocellulose membrane and immunoblotted for phospho-CRKL
(py207), phospho-Abl (py245) and phospho-BCR-ABL (pY245) anti-
bodies (Cell Signaling Technology). Signals were detected with HRP-
conjugated secondary antibody using the ECL kit (Amersham). CML
cell line K562 was included as a positive control. p-CRKL expression
levels were determined by densitometry using ImageJ software (NIH).
4.8. Cell proliferation assay
Total lin−CD34+, lin−CD34+CD38− or lin−CD34+CD38+ were
plated in triplicate in 96-well plate at 103 cells/well. Cells were then cul-
tured in SFM with or without 5 μM imatinib. When speciﬁed, the
300ngml−1 of OLFM4 (Acro Biosystem)or the following growth factors34+ cells. (a) Principal component (PC) analysis of global gene expression in iCD34+ cells
of CML iCD34+ cells shifted toward normal non-treated BM iCD34+ cells. (b) Selection of
iﬁcantly upregulated by imatinib in CML iCD34+(≥2 fold induction). Upper right Venn di-
ith tpm b 10 across all studied samples were excluded from analysis. (c) Heatmaps show-
differentially expressed genes are arranged based on ratio of expression in imatinib-treated
expression of OLFM4mRNA isoforms in CML and BM iCD34+ cells. The results are mean±
ted control. (e) OLFM4 knockdownwith siRNA induced apoptosis in imatinib treated CML
ences were only observed between CML iCD34+ samples treated with imatinib alone and
liferation in CSSMmedium supplementedwith growth factors. Graph displays the ratio of
res treated with scrambled siRNA. Results are mean ± SEM of three independent experi-
ble siRNA cultures) in CML iCD34+ cultures when compared to normal BM controls.
687K. Suknuntha et al. / Stem Cell Research 15 (2015) 678–693were added: 10 ng ml−1 IL3, 100 ng ml−1 SCF, 100 ng ml−1 Flt3L,
100 ng ml−1 IL6, and 200 ng ml−1 GM-CSF. Viable cell yields were de-
termined by counting trypan blue excluding viable cells using a
hemocytometer.4.9. Long-term culture initiating cell assay (LTC-IC)
Sorted iPSC-derived lin−CD34+CD45+ cells were plated in a six-
well plate at 104 cells/well containing 5–7 day-old cultures of murine
Fig. 5.Expression of OLFM4 in somatic CD34+ cells fromCMLpatients in chronic phase. (a) Expression ofOLFM4mRNA isoforms in freshly isolated lin−CD34+ (sCD34+)and sCD34− cells
from CML patients and normal controls, as determined by RT-PCR. iCD34− cells were used as a positive control (Pos). L is DNA ladder. (b) qPCR analysis of the expression of OLFM4mRNA
isoforms in sCD34+ and sCD34− cells from P1 and P6 CML patients. * p b 0.05 (c) Confocal microscopy showing the expression of OLFM4 in CD34+ cells (arrow) in the bonemarrow (BM)
biopsy specimen from normal donor and CML patient (scale bar= 20 μm). (d) Quantitation of OLFM4 production in sCD34+ cultures by ELISA. The lin−CD34+ cells from patients P1 and
P6 were cultured in serum-free medium with 1 ng ml−1 SCF, IL3, IL6 and Flt3L with or without 10 ng ml−1 G-CSF, 5 μM imatinib, or together for 24 h.
688 K. Suknuntha et al. / Stem Cell Research 15 (2015) 678–6931 × 105 M2-10B4 and OP9 stromal cells (1:1 ratio mix) in a LTC-IC me-
dium consisting of SFM supplemented with 10 μM hydrocortisone,
50 ng ml−1 SCF, 5 ng ml−1 IL3, and 50 ng ml−1 IL6. Cultures were
maintained at 37 °C in a humidiﬁed atmosphere with 5% CO2, and fed
at weekly intervals. After ﬁve weeks, cells were harvested and analyzed
for CFC potential as described above. LTC-IC assay for somatic lin−
CD34+CD45+ cells was performed using M2-10B4 cells exactly as de-
scribed in the Stem Cell Technologies protocol (http://www.stemcell.
com/en/Technical-Resources/db5a9/28412_ltc_ic-H.aspx). When indi-
cated, cells were pretreated for one week with 5 μM imatinib or DMSO
(control), in SFM supplemented with low concentration of growth fac-
tors (1 ngml−1 of each SCF, IL3, IL6, Flt3L and GM-CSF), and transferred
to LTC-IC cultures for an additional ﬁve weeks of culture. In someexperiments, cells were transfectedwith either OLFM4 or negative con-
trol siRNA and then pretreated with imatinib or DMSO as described
above.
4.10. IC50 assay
The lin−CD34+ and lin+CD34− cells were plated at 103 cells/well in
a 96-well plate in CSSM containing 10 ng ml−1 IL3, 100 ng/ml IL6,
200 ng ml−1 GM-CSF, 100 ng ml−1 SCF, and 100 ng ml−1 Flt3L with
0–100 μM imatinib. After 24 h of culture, a viable cell count was per-
formed using trypan blue. The IC50 was determined as the drug concen-
tration where cell death was 50% of maximum in the upper plateau
(Sebaugh, 2011). Data from three assays performed in triplicate were
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ative IC50 were determined by ﬁtting an exponential dose–response
curve to the cell proliferation data by using GraphPad Prism software
(GraphPad, San Diego, CA).
4.11. CFSE tracking of cell division
Differentiated cells were labeled with 1 μM carboxy-ﬂuorescein
diacetate succinimidyl diester (CFSE; Molecular Probes, Eugene, OR)
as previously described (Copland et al., 2006; Holtz et al., 2002). These
cells were then incubated overnight in CSSM medium supplemented
with growth factors to allow excess unbound dye to leak out of the
cells. Cells cultured in the presence of 10 μg/ml mitomycin C (Sigma Al-
drich) were used to establish the CFSEmax (undivided cell population).
The next day, CFSEbright cells were sorted by FACArias to exclude non-
labeled and CFSEdim populations. These cells were then cultured forFig. 6. Effects of OLFM4 on somatic lin−CD34+ CML cells. (a) The effect of imatinib on express
cells were pretreated for 24 hwith imatinib and transferred to clonogenic cultures. Hematopoie
mean ± SEM of two experiments performed in triplicates. * p b 0.01 (b) Knockdown of OLFM4
fection with OLFM4 siRNA (siOLFM4) or scramble (negative control) siRNA, CML or normal bon
OLFM4 protein (300 ngml−1) for 24 h in serum-free mediumwith low concentrations of grow
ﬁve independent experiments. Signiﬁcant differences (* p b 0.05) were observed only in CML
(NBM1–NBM3). (c) Quantiﬁcation of OLFM4 protein in the media from 5-week LTC-IC culture
ences (* p b 0.01)were observed in cultures of CML sCD34+ transfectedwith scramble siRNA an
IC cultures of CML patients but not of normal bone marrow controls (NBM). Results are meanfour days in CSSM supplemented with growth factors with or without
5 μM imatinib. At the end of the culture period, cells were stained
with CD34-APC and 7AAD for ﬂow cytometry analysis. The percentage
of cells in each generation was determined using FlowJo software
(Tree Star, Ashland, OR), with the position of the parent generation set
on the basis of the ﬂuorescence proﬁle of undivided cells.
4.12. Adhesion assay
The lin−CD34+CD45+ cells were incubated in SFM supplemented
with 1 ng/ml each of SCF, IL-3, IL-6, Flt3L and GM-CSF, with andwithout
5 μM imatinib for 24 h. Cells were thenwashed and resuspended in SFM
and plated onto either ﬁbronectin- or BSA-coated wells of 96-well
plates at 103 cells/well. After 2 h, nonadherent and adherent fractions
were separated as described previously (Bhatia et al., 2001; Holtz et
al., 2002). Both fractions were plated in serum-containing StemMACSion of OLFM4a mRNA isoform in hematopoietic colonies from patients P1 and P6. sCD34+
tic colonieswere collected seven days after transfection and analyzed by qPCR. Results are
potentiates the inhibitory effect of imatinib on CML sCD34+ CFCs (G+ GM). After trans-
emarrow sCD34+were culturedwith or without 5 μM imatinib in presence or absence of
th factors and transferred to clonogenic medium. Results are the mean± SEM of three to
sCD34+ cultures, but not in normal bone marrow sCD34+ controls from three patients
s by ELISA. Results are mean ± SEM of three independent experiments. Signiﬁcant differ-
d siOLFM4. (d) Knockdown of OLFM4with siRNA dramatically reduced CFC output in LTC-
± SEM of three experiments. * p b 0.05. NBM= normal bone marrow.
Fig. 7. Effect of OLFM4 knockdownwith siRNA on in vivo survival of CML sCD34+. (a) Representative dot plots show human hCD45 vs. mousemCD45 labeling in freshly isolated bonemarrow
samples at 12–14 weeks after transplantation. The samples of sCD34+ cells from each CML patient were divided equally, treated with siOLFM4 or scramble siRNA and then injected into
retroorbital vein of NBSGWmice. Corresponding mice pairs injected with cells from patient 1 (P1) and 6 (P6) are shown. (b) Frequency of human CD45+ cells in bone marrow of NBSGW
mice transplanted with scrambled and OLFM4 siRNA. Each point shows individual mouse. & indicates a mice pair injected with 5000 lin−CD34+ (sCD34+) cells. All remaining pairs of mice
were injected with 10,000 sCD34+ cells. The differences between studied groups are signiﬁcant (* p= 0.0265). (c) Detection of BCR-ABL expression by RT-PCR in human CD45+ cells isolated
from bonemarrow of sixmice injectedwith scrambled siRNA. Pos= positive control (mRNA isolated from CML iCD34− cells), m=mouse, h=human. (d) The hypothetical model of OLFM4
action on primitive CML cells. OLFM4 produced by CD34+ and CD34− cells supports survival and expansion of the most primitive leukemia cells. Since imatinib enhances the production of
OLFM4, it can potentially affect the survival of primitive leukemia cells through modulation of OLFM4-mediated signaling.
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adherent fraction was calculated.
4.13. Immunoﬂuorescence microscopy
Heat-induced antigen-retrieved parafﬁn sections of bone marrow
biopsy from normal subjects and CML patients (N = 2 each) were
stained with mouse anti-human CD34 (Ventana), and rabbit anti-
human OLFM4 (Abcam), or matched IgG isotype primary antibodies.
After staining with secondary antibodies, anti-mouse IgG Alexa Fluor
555 and anti-rabbit IgG Alexa Fluor 488 (Life Technology), and DAPI,
pictures were acquired by Nikon Eclipse Ti-E conﬁgured with an A1R
confocal system (Nikon Instruments Inc. Melville, NY) and Nikon Ele-
ments (NIS — element C) imaging software (Nikon Instruments Inc.
Melville, NY).
4.14. Detection of OLFM4 by ELISA
The lin−CD34+ cells from patients P1 and P6 (2000 cells per well)
were cultured in 120 μl serum-free medium with 1 ng ml−1 SCF, IL3,
IL6 and Flt3L with or without 10 ng ml−1 G-CSF, 5 μM imatinib, or to-
gether for 24 h. For G-CSF neutralization, cells treated with cultures
treated with 0.03 μg ml−1 mouse human G-CSF neutralizing antibody
(clone #3316 R&D Systems). OLFM4 protein in cultures was quantiﬁed
using a sandwich ELISA kit (USCN Life Science) according to manufac-
turer instruction.
4.15. siRNA transfection
OLFM4 siRNA composed of fourOLFM4-speciﬁc siRNAs (siOLFM4) or
control scrambled siRNA (AllStars Neg. siRNA AF 488) were obtained
from Qiagen. iPSCs-derived lin−CD34+CD45+ and somatic CML bone
marrow lin−CD34+ cells were transfected with a total 100 nM of either
OLFM4 or scrambled siRNA using the HiPerfect transfection reagent ac-
cording to the manufacturer's protocol (all from Qiagen). The transfec-
tion efﬁciency was 50–60% as evaluated by using control ALLStars Neg.
siRNAAF488. As determined by qPCR performed 24 h after transfection,
the silencing efﬁciency was 60–85% (Supplementary Fig. S4b).
4.16. Gene expression analysis by real-time PCR (qPCR)
RNA was isolated from the cell subpopulations using the PureLink
RNA mini kit (Life Technologies). cDNA synthesis was carried out
using Advantage RT-for-PCR kit (Clontech). Quantitative real-time PCR
analysis was performed using the PlatinumSYBR Green qPCR
SuperMix-UDG kit (Life Technologies) and primers listed in Supple-
mentary Table S5. The reactions were run on a Mastercyclerep realplex
thermal cycler (Eppendorf) and expression levels were calculated by
minimal cycle threshold values (Ct) normalized to the reference expres-
sion of GAPDH in each sample (Pfafﬂ, 2001). When speciﬁed, K562 was
used as a reference. All qPCR products were analyzed on 1.2% agarose
gels to conﬁrm the speciﬁcity of detection.
4.17. RNA-Seq analysis
Day 11 iCD34+ cells were isolated and cultured CSSM supplemented
with 200 ngml−1 of GM-CSFwith DMSO or 5 μmof imatinib. After 16 h,
total RNA from cells was isolatedwith PureLink RNAmini kit (Life Tech-
nologies) and treated with DNaseI TURBO DNase™ kit (Ambion). Total
RNA was quantitated using the Life Technologies Qubit ﬂuorometer
(Q32857) and the Agilent Bioanalyzer 2100. Samples were then pre-
pared for sequencing using the Illumina TruSeq RNA Sample Prepara-
tion Kit v2 (RS-122-2001), according to the manufacturer's protocol.
Final sample libraries were quantitated with the Life Technologies
Qubit ﬂuorometer and sequenced on the Illumina HiSeq 2500 (SY-
401-1003-PRE). Base-calling and demultiplexing were done with theIllumina Genome Analyzer Casava Software, version 1.8.2. Following
quality assessment and ﬁltering for adapter molecules and other se-
quencing artifacts, the remaining sequencing reads were aligned to
19,084 RefSeq genes extracted from the Illumina iGenomes annotation,
selecting only “NM_” designated genes. Bowtie v 0.12.9 was used,
allowing two mismatches in a 28 bp seed, and excluding reads with
more than 200 alignments (Langmead et al., 2009). RSEM v 1.2.3 was
used to estimate isoform or gene relative expression levels in units of
“transcripts per million” (tpm) (Li and Dewey, 2011; Li et al., 2010).
To determine differentially expressed genes, RNAseq output data were
analyzed using EBseq(v.1.1.6) http://www.biostat.wisc.edu/~kendzior/
EBSEQ/ (Leng et al., 2013). Genes with a posterior probability equal to
1.000 were considered differentially expressed. Genes with tpm b 10
across all studied samples were excluded from analysis. Remaining
genes demonstrating signiﬁcant differences in expression between the
studied groups were assigned to biological process categories using
the DAVID bioinformatics program (Huang da et al., 2008). To visualize
the gene-expression levels, a heat-map was composed using
MultiExperiment Viewer v4.2 (http://www.tm4.org). PCA was per-
formed with TPM (transcripts per million) normalized data using
“stats” package for R programming language, with “scale” option dis-
abled. The data was preliminary restricted to genes that were called dif-
ferentially expressed between CML-control and CML-Imatinib with
Benjamini-Hochberg false discovery rate below 0.01.
4.18. Animal transplantation
Engraftment of sCD34+ cells was evaluated using NBSGW mice
possessing a defective Kit allele; (c-kit, W41) (McIntosh et al., 2014).
Bone marrow lin−CD34+ cells from the CML patients in chronic phase
were equally divided and transduced with scramble siRNA or siOLFM4.
5000 or 10,000 lin−CD34+ cells were injected into the retroorbital vein
of NBSGW mice. Animals were analyzed at 12–16 weeks after trans-
plantation by ﬂow cytometry and presence of BCR-ABL transcripts was
conﬁrmed by RT-PCR. To evaluate BCR-ABL expression in engrafted
cells, bone marrow samples from transplanted animals were cultured
in SFM with human SCF, IL3, IL6 and Flt3L (each at 100 ng ml−1) to ex-
pand human cells. After 6–7 days of culture, human CD45+ cells were
isolated by FACS and analyzed by for BCR-ABL expression by RT-PCR.
4.19. Statistical analysis
Data obtained from multiple experiments were reported as the
mean ± SEM. Signiﬁcance levels were determined by one-tailed
Student-t test analysis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.10.015.
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